Tokio Marine Asset Management Co. Ltd. Acquires 326 Shares of Illumina, Inc. (NASDAQ:ILMN)

Tokio Marine Asset Management Co. Ltd. grew its stake in Illumina, Inc. (NASDAQ:ILMN) by 7.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,978 shares of the life sciences company’s stock after acquiring an additional 326 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Illumina were worth $649,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. UMB Bank n.a. lifted its stake in Illumina by 7.0% in the second quarter. UMB Bank n.a. now owns 1,341 shares of the life sciences company’s stock valued at $140,000 after acquiring an additional 88 shares during the last quarter. Integrated Advisors Network LLC lifted its stake in Illumina by 2.0% in the 3rd quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock valued at $585,000 after purchasing an additional 90 shares during the last quarter. Carson Advisory Inc. grew its holdings in Illumina by 3.8% during the third quarter. Carson Advisory Inc. now owns 2,757 shares of the life sciences company’s stock worth $360,000 after purchasing an additional 102 shares during the period. Huntington National Bank increased its position in Illumina by 29.4% during the third quarter. Huntington National Bank now owns 515 shares of the life sciences company’s stock worth $67,000 after buying an additional 117 shares during the last quarter. Finally, Institute for Wealth Management LLC. lifted its position in shares of Illumina by 4.6% in the second quarter. Institute for Wealth Management LLC. now owns 2,728 shares of the life sciences company’s stock valued at $285,000 after buying an additional 119 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on ILMN shares. Stephens lifted their price objective on shares of Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Piper Sandler reduced their target price on shares of Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a report on Monday, November 11th. Royal Bank of Canada increased their price target on shares of Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. Argus upgraded Illumina from a “hold” rating to a “buy” rating and set a $150.00 price objective for the company in a report on Wednesday, August 28th. Finally, Barclays increased their target price on Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Illumina presently has an average rating of “Moderate Buy” and an average price target of $164.00.

Illumina Stock Performance

NASDAQ:ILMN opened at $135.05 on Friday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. Illumina, Inc. has a fifty-two week low of $92.69 and a fifty-two week high of $156.66. The firm has a market capitalization of $21.42 billion, a PE ratio of -13.56 and a beta of 1.13. The stock’s fifty day moving average is $139.66 and its 200 day moving average is $124.30.

Illumina (NASDAQ:ILMN) last released its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same quarter last year, the firm posted $0.33 earnings per share. The business’s revenue was down 3.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Illumina, Inc. will post 4.11 earnings per share for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.